One-Year Mortality After Lung Transplantation: Experience of a Single French Center Between 2012 and 2021

Overview

Journal Ann Transplant

Specialty General Surgery

Date 2024 Aug 20

PMID 39161071

Authors

Thi Cam Tu Hoang

Lien Han

Sandrine Hirschi

Tristan Degot

Justine Leroux

Pierre-Emmanuel Falcoz

Anne Olland

Nicola Santelmo

Marion Villard

Olivier Collange

Gauthier Appere

Romain Kessler

Benjamin Renaud-Picard

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Lung transplantation (LTx) is a life-extending therapy for specific patients with terminal lung diseases. This study aimed to evaluate the associations and causes of 1-year mortality after lung transplantation at Strasbourg University Hospital, France, between 2012 and 2021. MATERIAL AND METHODS We carried out a retrospective analysis on 425 patients who underwent LTx at Strasbourg University Hospital between January 1, 2012, and December 31, 2021. Pre-transplant, perioperative, and postoperative data were collected from the electronic medical records. RESULTS Among all patients, 94.6% had a LTx, 4.0% a heart-lung transplantation, and 1.4% underwent pancreatic islet-lung transplantation. The median age at transplantation was 57 years, with 55.3% male patients. The main native lung disease leading to LTx was chronic obstructive pulmonary disease in 51.1% of patients; 16.2% needed super-urgent LTx. The 1-year mortality rate was 11.5%. Most deaths were either caused by multi-organ failure or septic shock. In our multivariate analysis, we identified 3 risk factors significantly related to 1-year mortality after LTx: body mass index (BMI) between 25 and 30 kg/m² vs BMI between 18.5 and 25 kg/m² (P=0.032), postoperative extracorporeal membrane oxygenation support (P=0.034), and intensive care unit length of stay after transplantation (P<0.001). Two other factors were associated with a significantly lower 1-year mortality risk: longer hospital stay after LTx (P=0.024) and tacrolimus prescription (P=0.004). CONCLUSIONS Our study reported a 1-year mortality rate of 11.5% after LTx. Although LTx candidates are carefully selected, additional data are required to improve understanding of the risk factors for post-LTx mortality.

References

Fernandez R, Safaeinili N, Kurihara C, Odell D, Jain M, DeCamp M . Association of body mass index with lung transplantation survival in the United States following implementation of the lung allocation score. J Thorac Cardiovasc Surg. 2017; 155(4):1871-1879.e3. PMC: 6637420. DOI: 10.1016/j.jtcvs.2017.11.031. View

Tran-Dinh A, Guiot M, Tanaka S, Lortat-Jacob B, Atchade E, Zappella N . Bacteraemia Is Associated with Increased ICU Mortality in the Postoperative Course of Lung Transplantation. Antibiotics (Basel). 2022; 11(10). PMC: 9598225. DOI: 10.3390/antibiotics11101405. View

Tanaka S, Geneve C, Tebano G, Grall N, Piednoir P, Bronchard R . Morbidity and mortality related to pneumonia and TRACHEOBRONCHITIS in ICU after lung transplantation. BMC Pulm Med. 2018; 18(1):43. PMC: 5836426. DOI: 10.1186/s12890-018-0605-9. View

Sabashnikov A, Weymann A, Mohite P, Zych B, Patil N, Garcia Saez D . Risk factors predictive of one-year mortality after lung transplantation. Eur J Cardiothorac Surg. 2014; 46(6):e82-8. DOI: 10.1093/ejcts/ezu383. View

Thabut G, Mal H . Outcomes after lung transplantation. J Thorac Dis. 2017; 9(8):2684-2691. PMC: 5594127. DOI: 10.21037/jtd.2017.07.85. View

Foroutan F, Malik A, Clark K, Buchan T, Yang H, Cheong G . Predictors of 1-year mortality after adult lung transplantation: Systematic review and meta-analyses. J Heart Lung Transplant. 2022; 41(7):937-951. DOI: 10.1016/j.healun.2022.03.017. View

Renaud-Picard B, Koutsokera A, Cabanero M, Martinu T . Acute Rejection in the Modern Lung Transplant Era. Semin Respir Crit Care Med. 2021; 42(3):411-427. DOI: 10.1055/s-0041-1729542. View

Ghaidan H, Fakhro M, Lindstedt S . Impact of allograft ischemic time on long-term survival in lung transplantation: a Swedish monocentric study. Scand Cardiovasc J. 2020; 54(5):322-329. DOI: 10.1080/14017431.2020.1781240. View

Plantier L, Skhiri N, Biondi G, Jebrak G, Himbert D, Castier Y . Impact of previous cardiovascular disease on the outcome of lung transplantation. J Heart Lung Transplant. 2010; 29(11):1270-6. DOI: 10.1016/j.healun.2010.05.010. View

10.

Krustrup D, Iversen M, Martinussen T, Andersen C . Time elapsed after transplantation influences the relationship between the number of regulatory T cells in lung allograft biopsies and subsequent acute rejection episodes. Transpl Immunol. 2014; 31(1):42-7. DOI: 10.1016/j.trim.2014.04.007. View

11.

Noguchi Machuca T, Schio S, Camargo S, Lobato V, Costa C, Felicetti J . Prognostic factors in lung transplantation: the Santa Casa de Porto Alegre experience. Transplantation. 2011; 91(11):1297-303. DOI: 10.1097/TP.0b013e31821ab8e5. View

12.

Treede H, Glanville A, Klepetko W, Aboyoun C, Vettorazzi E, Lama R . Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant. 2012; 31(8):797-804. DOI: 10.1016/j.healun.2012.03.008. View

13.

Lee S, Park M, Song J, Kim Y, Lee J, Paik H . Perioperative factors associated with 1-year mortality after lung transplantation: a single-center experience in Korea. J Thorac Dis. 2017; 9(10):4006-4016. PMC: 5723833. DOI: 10.21037/jtd.2017.09.21. View

14.

Banga A, Mohanka M, Mullins J, Bollineni S, Kaza V, Ring S . Hospital length of stay after lung transplantation: Independent predictors and association with early and late survival. J Heart Lung Transplant. 2016; 36(3):289-296. DOI: 10.1016/j.healun.2016.07.020. View

15.

Upala S, Panichsillapakit T, Wijarnpreecha K, Jaruvongvanich V, Sanguankeo A . Underweight and obesity increase the risk of mortality after lung transplantation: a systematic review and meta-analysis. Transpl Int. 2015; 29(3):285-96. DOI: 10.1111/tri.12721. View

16.

Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B . Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003; 125(4):891-900. DOI: 10.1067/mtc.2003.71. View

17.

Leard L, Holm A, Valapour M, Glanville A, Attawar S, Aversa M . Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021; 40(11):1349-1379. PMC: 8979471. DOI: 10.1016/j.healun.2021.07.005. View

18.

Atchade E, Boughaba A, Tran Dinh A, Jean-Baptiste S, Tanaka S, Copelovici L . Prolonged mechanical ventilation after lung transplantation: risks factors and consequences on recipient outcome. Front Med (Lausanne). 2023; 10:1160621. PMC: 10203407. DOI: 10.3389/fmed.2023.1160621. View

19.

Hackman K, Bailey M, Snell G, Bach L . Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant. 2014; 14(2):438-45. DOI: 10.1111/ajt.12561. View

20.

Yusen R, Edwards L, Dipchand A, Goldfarb S, Kucheryavaya A, Levvey B . The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016; 35(10):1170-1184. DOI: 10.1016/j.healun.2016.09.001. View